NGOZI OKAFOR: Open Payments
NPI 1699490243 · VINELAND, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,355 in 80 payments from 12 companies in 2025. Trend: 2023 $1,307 · 2024 $1,762 · 2025 $1,355
Food & beverage: $1,355
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $350 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $214 |
| Neurocrine BioSciences, Inc. | 10 | $182 |
| Vanda Pharmaceuticals Inc. | 8 | $149 |
| Janssen Pharmaceuticals, Inc | 5 | $100 |
| Lundbeck LLC | 4 | $75 |
| Teva Pharmaceuticals USA, Inc. | 4 | $64 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| E.R. Squibb & Sons, L.L.C. | 3 | $52 |
| Alkermes, Inc. | 3 | $48 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, FANAPT, REXULTI, INVEGA, COBENFY, Qelbree.
Industry payments across NJ — which companies pay providers there.
